Company Profile
BeBetter Med Inc., a biopharmaceutical company provides the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases. It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor.
Its portfolio also includes BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor, BEBT-109, a pan-mutant EGFR inhibitor for antitumor, BEBT-260, a ChK1 inhibitor for antitumor, BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease, BEBT-503, a pan-PPAR agonist for metabolic disease, BEBT-607, a KRAS G12C inhibitor for antitumor, BEBT-808, an oral small molecule GLP-1R full agonist for metabolic disease, BEBT-809, a GPR75 pathway inhibitor for metabolic disease, and BEBT-508, a small nucleic acid drug. Founded in 2012, the company is based in Guangzhou, China.